Ericox

Etoricoxib

Acute & chronic treatment of signs & symptoms of OA & RA; ankylosing spondylitis (AS); acute gouty arthritis & pain including primary dysmenorrhoea & minor dental procedures.

OA 30 or 60 mg once daily. Not to exceed 60 mg daily. RA & AS 60 or 90 mg once daily. Not to exceed 90 mg daily. Acute gouty arthritis & pain, primary dysmenorrhea Not to exceed 120 mg daily. Max duration of treatment: 8 days. Minor dental procedures Not to exceed 90 mg once daily. Max duration of treatment: 8 days. Mild hepatic insufficiency (Child-Pugh score 5-6) Not to exceed 60 mg once daily. Moderate hepatic insufficiency (Child-Pugh score 7-9) Not to exceed 60 mg every other day.

May be taken with or without food.

Hypersensitivity. Active peptic ulceration or GI bleeding; inflammatory bowel disease; CHF (NYHA II-IV); uncontrolled HTN; increased risk of CV disease eg, ischaemic heart disease & stroke; peripheral arterial disease &/or cerebrovascular disease. Experienced allergic-type reaction w/ ASA or NSAIDs eg, COX-2 inhibitors. Severe hepatic dysfunction (serum albumin <25 g/L or Child-Pugh ≥10); estimated renal CrCl <30 mL/min. Pregnancy & lactation. Childn & adolescents <16 yr.

Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity; persistent abnormal LFTs are detected. Not a substitute for ASA in prophylaxis of CV thromboembolic diseases. Increased risk of GI ulceration, bleeding & perforation. History of serious GI events & other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy; cardiac failure, left ventricular dysfunction, preexisting oedema. Significant risk factors for CV events eg, HTN, hyperlipidaemia, DM; heart disease, peripheral arterial disease. May mask fever & other signs of inflammation. Ensure adequate hydration prior to therapy. Monitor BP 2 wk after initiation & periodically thereafter. Monitor renal function in patients w/ preexisting significant renal impairment, uncompensated heart failure or cirrhosis. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Concomitant use w/ NSAIDs, other NSAIDs or ASA even at low doses; warfarin or other oral anticoagulants. Not recommended in advanced renal disease (CrCl <30 mL/min). May affect ability to drive & use machines. Renal or hepatic dysfunction. Not recommended in women of childbearing potential. Not to be used during pregnancy & lactation. Elderly, debilitated patients.

Abdominal pain. Alveolar osteitis; oedema/fluid retention; dizziness, headache; palpitations, arrhythmia; HTN; bronchospasm; constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer; increased ALT & AST; ecchymosis; asthenia/fatigue, flu-like disease.

Increased prothrombin time w/ oral anticoagulants. Reduced effects of diuretics, ACE inhibitors, AIIAs. Increased rate of GI ulceration w/ low-dose ASA. Increased nephrotoxic effect of cyclosporin or tacrolimus. Increased lithium plasma levels. Increased risk of MTX-related toxicity. Increased steady-state AUC of ethinyl estradiol, unconjugated estrogens. Increased C_max of digoxin. Decreased plasma conc w/ rifampicin. Drugs metabolised by sulfotransferases eg, salbutamol PO, minoxidil.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

B